JEGI LEONIS ha asesorado a Forge en su acuerdo definitivo para adquirir Becker's Healthcare

Apollo-backed Forge has agreed to acquire Pamlico Capital portfolio company Becker's Healthcare, expanding Forge's healthcare and life-sciences media footprint. Becker's reaches more than 1.5 million healthcare leaders and attracts over 15,000 annual live-event attendees; combined with Forge's Fierce Healthcare and Life Sciences business, it will form a year-round omnichannel platform spanning biotech, pharma, providers and payers with more than 35 in-person events. The transaction advances Forge's scale strategy in structurally growing healthcare-information and executive-community markets, though no financial terms were disclosed.

Analysis

For APO, the financial impact is likely immaterial at the management-fee level, but the transaction is directionally supportive of Apollo's ability to create value through platform consolidation rather than relying solely on multiple expansion. The relevant mechanism is cross-selling: combining hospital-system decision makers with biopharma, payer, and life-sciences advertisers can raise first-party data value, sponsorship yield, and event utilization. Those synergies typically require 12-24 months and depend on retaining editorial credibility and executive-community engagement; aggressive monetization could erode the asset being acquired.

Public-market read-through is limited because the operating assets are private and transaction valuation, leverage, and pro forma EBITDA are undisclosed. The more actionable second-order implication is for fragmented B2B information and events businesses: scarce vertical audiences with recurring subscriptions, proprietary data, and executive-event franchises should command better strategic interest, while generalist ad-supported media remains structurally disadvantaged. Near term, this is not a standalone APO earnings catalyst; it modestly reinforces the private-equity rollout thesis but does not change the stock's primary sensitivity to fundraising, realizations, credit performance, and fee-related earnings.

The contrarian risk is that healthcare marketing budgets are increasingly scrutinized amid provider cost pressure and pharma commercialization rationalization. If healthcare event attendance or digital lead-generation spending weakens, the combined platform may face integration costs before revenue synergies arrive, reducing exit-multiple support for Apollo's portfolio. Thesis would be strengthened by disclosed recurring-revenue mix, attendee retention, and net leverage; it is weakened if Forge pursues additional debt-funded acquisitions before demonstrating organic growth and margin realization.

Key Decisions for Investors

• No incremental standalone trade in APO solely on this transaction; retain APO exposure only within the broader alternatives-manager thesis, with the next 1-3 month decision points being fundraising, deployment and fee-related-earnings disclosures rather than integration headlines.
• Create a watchlist of publicly traded B2B information/data peers with healthcare or professional-audience exposure, including RELX and WOLTERS KLUWER, for strategic-premium support; favor names with subscription/data revenue over advertising-dependent media if M&A appetite broadens over 6-18 months.
• For APO holders, treat disclosure of transaction leverage, purchase multiple, and Forge's pro forma EBITDA as gating data. A debt-funded acquisition program without visible organic growth or synergy milestones would be a negative signal for portfolio-level value creation, not a reason to add exposure.
• Monitor provider and pharma commercial-spend indicators over the next two quarters. A material deterioration in hospital capital budgets, conference attendance, or pharma selling-and-marketing guidance would challenge the monetization case and favor avoiding event-heavy media exposures.